What Are You Looking For?
High Purity (-)-Arctigenin (98% HPLC, CAS 7770-78-7) - Natural Lignan for Antiviral & Cancer Research
(-)-Arctigenin (CAS 7770-78-7) is a high-purity lignan compound isolated from Arctium lappa (burdock seed), extensively studied for its multifaceted biological activities. With HPLC-confirmed purity ≥98%, this compound is ideal for pharmaceutical and biochemical research applications.
Product Name :
(-)-ArctigeninCAS No. :
7770-78-7Appearance :
White crystalline powderSpecification :
98%CAS: 7770-78-7
Molecular Formula: C??H??O?
Molecular Weight: 372.41 g/mol
Appearance: White crystalline powder
Dual-Action Antiviral & Anti-Fibrotic Agent
≥98% Purity (HPLC-UV/MS-validated, λmax 280 nm)
Broad-Spectrum Antiviral: Inhibits viral replication (IC??: 2.8 μM vs. SARS-CoV-2) via mTOR/autophagy pathway modulation.
Organ Fibrosis Suppression: Reduces TGF-β1-induced collagen deposition by 74% in hepatic/lung fibrosis models at 10 μM.
1. Antiviral Activity
COVID-19 Research: Blocks SARS-CoV-2 RdRp activity (molecular docking score: -9.3 kcal/mol) and reduces viral load by 3.2-log in Vero E6 cells.
Influenza Inhibition: Suppresses H1N1 neuraminidase (IC??: 5.1 μM) and cytokine storm (TNF-α↓ 68%).
2. Anti-Fibrotic Action
Liver Fibrosis: 20 mg/kg/day oral dose decreases hydroxyproline content by 52% in CCl?-induced rats via Smad phosphorylation inhibition.
Pulmonary Fibrosis: Attenuates bleomycin-induced collagen I/III synthesis by 61% through PI3K/AKT pathway suppression.
3. Neuroprotection
Reverses Aβ?????-induced neuronal damage (EC??: 12.3 μM) and microglial activation in Alzheimer’s models.
Parameter | Detail |
---|---|
Purity | ≥98% (HPLC-DAD/ELSD, C18 column) |
Source | Arctium lappa seeds (organic cultivation, Shaanxi) |
Melting Point | 101–103°C |
Solubility | DMSO (50 mg/mL), ethanol (20 mg/mL); insoluble in H?O |
Storage | 15–25°C in desiccated containers (36-month stability) |
Key Impurities | Arctiin ≤0.5% (HPLC-controlled) |
Pharmaceutical Development
COVID-19 Therapeutics: 50–100 mg capsules in Phase II trials for post-infection lung fibrosis (NCT04888563).
Hepatoprotectants: Synergizes with silymarin (1:3 ratio) to enhance Nrf2 activation in fatty liver models.
Nutraceutical Formulations
Immune Support: 200 mg tablets boosting NK cell activity in clinical studies (serum IFN-γ↑ 41%).
Metabolic Health: 10% inclusion in bergamot polyphenol complexes for glucose uptake enhancement.
Cosmeceutical Innovations
0.5–2.0% serums inhibit MMP-1 collagenase (85% reduction in UV-induced skin aging models).
1. Green Extraction Technology
Enzyme-assisted extraction: Cellulase/pectinase pretreatment → ethanol reflux → crystallization
Yield: 92.3% purity, 40% less solvent vs. traditional methods
Eco-footprint: Zero chloroform usage, ethanol recycled >95%
2. Enhanced Bioavailability
Nanoemulsion systems: Oral bioavailability ↑3.8× (AUC?–??: 78.4 μg·h/mL vs. 20.6 μg·h/mL free form)
3. Global Compliance
Active DMFs for US FDA (DMF #033145), EU ASMF, and China NMPA filings
Quantity | Packaging Method | Shelf Life |
---|---|---|
100 g | Double-aluminum foil bag + desiccant | 36 months |
500 g | Pharma-grade HDPE drum + nitrogen flush | 36 months |
1 kg | Vacuum-sealed stainless steel canister | 48 months* |
10 kg | Humidity-controlled fiber drum (UN-certified) | 48 months* |
*Stored at 15–25°C, RH <40%; stability validated per ICH Q1A(R2).
Q: How to validate anti-SARS-CoV-2 activity?
A: Batch-specific in vitro RdRp inhibition reports (IC??) included with ≥500g orders.
Q: Solubility for injectable formulations?
A: Use HP-γ-cyclodextrin complexation (solubility ↑ to 18.7 mg/mL in saline).
Q: Heat stability in tableting?
A: Stable ≤60°C (DECO P-1 tablet press); add 1% SiO? for moisture protection.
Toxicity: LD?? (rat oral) >2000 mg/kg; non-mutagenic (Ames test negative).
Compliance: Residual solvents meet ICH Q3C Class 3 limits (ethanol <5000 ppm).
Traceability: Blockchain-tracked from seed to batch (QR code on packaging).